Noxopharm Ltd (ASX:NOX) has completed a review of safety data from the dose escalation phase of the DARRT-2 trial assessing the effect of Veyonda ® in combination with low-dose external beam radiotherapy on metastatic cancers.
The third and final dosage of 1600 milligrams was given to cohort three and found to be safe.
No further dose escalations are required and the trial will now progress to part two, which will evaluate efficacy signals for the treatment while safety data continues to be collected.
Noxopharm expects to begin the second part of the trial late this quarter or early in the second quarter of this year pending some protocol requirements.
Proceeding according to schedule
“This meeting marks a positive development in the progress of DARRT-2,” Noxopharm CEO Dr Gisela Mautner said.
“We are proceeding according to schedule as we now wind down the first part of the trial and look to start focusing on efficacy in the very near future.
“As stated in the recent AGM, we are actively exploring ways to reduce patient numbers and costs while bringing forward efficacy data.
“And when results are meaningful, we will target data releases via high-profile conferences and peer-reviewed publications to maximise commercial potential.”